Patent application number | Description | Published |
20110117079 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 05-19-2011 |
20110250130 | TNF-ALPHA BINDING PROTEINS - Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 10-13-2011 |
20110256138 | AMYLOID-BETA BINDING PROTEINS - The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided. | 10-20-2011 |
20110318349 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 12-29-2011 |
20130164256 | IMMUNOBINDERS DIRECTED AGAINST TNF - Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 06-27-2013 |
20140079705 | BISPECIFIC IMMUNOBINDERS DIRECTED AGAINST TNF AND IL-17 - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 03-20-2014 |
20140093521 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 04-03-2014 |
20140170152 | IMMUNOBINDERS DIRECTED AGAINST TNF - Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 06-19-2014 |
20140178389 | IL-1 BINDING PROTEINS - The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation. | 06-26-2014 |
20140221621 | SINGLE-CHAIN MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS - Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display). | 08-07-2014 |
20140235476 | MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS FOR IDENTIFYING VARIANTS OF SAME - Provided are protein, nucleic acid, and cellular libraries of multivalent binding proteins (e.g., DVD-Fab or DVD-Ig molecules) and the use of these libraries for the screening of multivalent binding proteins using cell surface display technology (e.g., yeast display). | 08-21-2014 |
20140243228 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES - System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity. | 08-28-2014 |